The global peptide-based anti-obesity market is projected to grow at 8.2% CAGR, driven by targeted therapies and increasing R&D investment. Here’s what it means for suppliers and researchers.
We are proud to announce that our manufacturing facility has successfully passed the rigorous Good Manufacturing Practice (GMP) audit, reinforcing our commitment to quality and reliability for global partners.